Urethritis in men: Difference between revisions

Line 31: Line 31:


===Recurrent or Persistent===
===Recurrent or Persistent===
''Target [[M. genitalium]], a common cause of persistent nongonococcal urethritis''
''Target [[M. genitalium]]''
*[[Azithromycin]] 1 gm PO x 1 (if not administered in the initial regimen), '''OR'''
*[[Azithromycin]] 1 gm PO x 1 (if not administered in the initial regimen), '''OR'''
*[[Moxifloxacin]] 400 mg daily x 7 days (if the initial failed regimen included azithromycin)
*[[Moxifloxacin]] 400 mg daily x 7 days (if the initial failed regimen included azithromycin)

Revision as of 11:11, 31 October 2017

Background

Genitourinary infection

(1) Human urinary system: (2) kidney; (3) renal pelvis; (4) ureter; (5) urinary bladder (6) urethra.
Additional structures: (7) adrenal gland; (8) renal artery and vein; (9) inferior vena cava; (10) abdominal aorta; (11) common iliac artery and vein; (12) liver; (13) large intestine; (14) pelvis.

"UTI" frequently refers specifically to acute cystitis, but may also be used as a general term for all urinary infections; use location-specific diagnosis.

Clinical Features

  • Dysuria
  • Urethral discharge

Differential Diagnosis

Dysuria

Evaluation

Workup

  • UA
  • Urine GC/chlamydia

Diagnosis

  • Typically initially a clinical diagnosis with empiric treatment

Management

Initial antimicrobial treatment is typically empiric, depending on risk for gonococcal versus nongonococcal urethritis

Gonococcal

Will also treat chlamydia

Nongonococcal

Chlamydia most likely pathogen

Recurrent or Persistent

Target M. genitalium

  • Azithromycin 1 gm PO x 1 (if not administered in the initial regimen), OR
  • Moxifloxacin 400 mg daily x 7 days (if the initial failed regimen included azithromycin)

Consider coverage of T. vaginalis, among men who have sex with women

  • Metronidazole 2 gm PO x 1, OR
  • Tinidazole 2 gm PO x 1

Disposition

  • Outpatient

See Also

References